Cargando…

Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies

Different rabbit polyclonal antilymphocyte globulins (ATGs) are used in allogeneic hematopoietic stem cell transplantation (alloHSCT) to prevent graft-versus-host disease (GvHD). We compared 2 different ATGs in alloHSCT after reduced intensity conditioning (RIC) for hematological malignancies. We re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paiano, Sandra, Roosnek, Eddy, Tirefort, Yordanka, Nagy-Hulliger, Monika, Masouridi, Stavroula, Levrat, Emmanuel, Bernimoulin, Michael, Huguet, Saadia, Casini, Alessandro, Matthes, Thomas, Samii, Kaveh, Passweg, Jakob R., Chalandon, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385613/ https://www.ncbi.nlm.nih.gov/pubmed/25874131 http://dx.doi.org/10.1155/2015/980924

Ejemplares similares

Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation
por: Simonetta, Federico, et al.
Publicado: (2019)

Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies
por: Levrat, Emmanuel, et al.
Publicado: (2015)

Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT
por: Mohty, B, et al.
Publicado: (2011)

A rare case of primary cutaneous follicle centre lymphoma presenting as a giant tumour of the scalp and combined with JAK2V617F positive essential thrombocythaemia
por: Tirefort, Yordanka, et al.
Publicado: (2014)

Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2016)

Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation
por: Pradier, Amandine, et al.
Publicado: (2020)

Very severe immune thrombocytopenia following SARS-CoV-2 vaccination requiring splenectomy: a case report
por: Weiner, Marc, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
por: Simeunovic, Helena, et al.
Publicado: (2022)

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients
por: Olearo, Flaminia, et al.
Publicado: (2020)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation in non‐Hodgkin lymphoma in Switzerland, 30 years of experience: Sooner is better
por: Rebmann, Ekaterina, et al.
Publicado: (2022)

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
por: Morin, Sarah, et al.
Publicado: (2023)

Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation
por: Glampedakis, Emmanouil, et al.
Publicado: (2021)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
por: Roth, Romain Samuel, et al.
Publicado: (2022)

Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
por: Kronig, Ilona, et al.
Publicado: (2021)

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
por: Calderin Sollet, Zuleika, et al.
Publicado: (2023)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Human pegivirus-1 replication influences NK cell reconstitution after allogeneic haematopoietic stem cell transplantation
por: Pradier, Amandine, et al.
Publicado: (2023)

Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma
por: Zanella, Marie-Céline, et al.
Publicado: (2023)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

Rhinovirus Infections among Hematopoietic Stem Cell Transplant Recipients: A Pre-Transplant Dilemma?
por: Barral, Sébastien, et al.
Publicado: (2022)

Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections
por: Roth, Romain Samuel, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2021)

T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Mamez, Anne-Claire, et al.
Publicado: (2022)

T315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
por: Noetzli, Jasmine, et al.
Publicado: (2017)

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
por: Masouridi-Levrat, Stavroula, et al.
Publicado: (2021)

P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
por: Mamez, A.-C., et al.
Publicado: (2022)

Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis
por: Bergeron, A, et al.
Publicado: (2012)

T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Pradier, A., et al.
Publicado: (2022)

Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling
por: Sommer, I E, et al.
Publicado: (2015)

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children
por: Lee, J W, et al.
Publicado: (2009)

Hematopoietic SCT in Europe: data and trends in 2011
por: Passweg, J R, et al.
Publicado: (2013)

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents
por: Shah, Nishi, et al.
Publicado: (2014)

Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
por: Toor, A, et al.
Publicado: (2008)

SCT Barrel
por: Marcelloni Oliveira, C
Publicado: (2005)

SCT barrel
por: Marcelloni Oliveira, C
Publicado: (2005)

Commissioning of the SCT
por: Hayward, H
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_9cm1lbu5n48gq2mvibbn7sfq4o